CD38 and lymphoma: Distinguishing minimal residual B-lymphoblastic leukemia/lymphoma from hematogones relies on the observation in residual leukemic blasts of discrete rather than variable expression of B cell markers that vary in expression during normal B cells development, such as CD10, CD38, CD20, and CD34, as well as the expression in leukemic blasts of any aberrant markers, such as myeloid or T cells markers, noted at the time of diagnosis (Table 2).